Electrophysiological and inotropic characterization of a novel class III antiarrhythmic agent, GLG-V-13, in the mammalian heart

Journal of Cardiovascular Pharmacology

Volumn 28, Issue 2, 1996, Pages 182-191

  Fazekas, Tamas ^a   Carlsson, Leif ^b   Scherlag, Benjamin J ^c,f   Mabo, Philippe ^d   Poty, Herve ^c   Palmer, Mattias ^b   Patterson, Eugene ^c   Berlin, K Darrell ^e   Garrison, Gregory L ^e   Lazzara, Ralph ^c  

^a UNIVERSITY OF SZEGED   (Hungary)

^b ASTRAZENECA R AND D   (Sweden)

^c UNIVERSITY OF OKLAHOMA   (United States)

^d RENNES UNIVERSITY HOSPITAL   (France)

^e OKLAHOMA STATE UNIVERSITY   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Dog; GLG V 13 Class III; Guinea pig; Monophasic action potential; Myocardial infarction; Rabbit

Indexed keywords

BICYCLO[3.3.1]NONANE DERIVATIVE; LIDOCAINE; POTASSIUM;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATRIOVENTRICULAR CONDUCTION; CHRONOTROPISM; DOG; DOSE RESPONSE; ELECTROCARDIOGRAM; ELECTROPHYSIOLOGY; ELECTROSTIMULATION; GUINEA PIG; HEART INFARCTION; HEART MUSCLE CELL; HEART PACING; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; INOTROPISM; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; QRS COMPLEX; RABBIT;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; DOGS; ELECTROPHYSIOLOGY; GUINEA PIGS; HEART; HEART ATRIA; HEMODYNAMIC PROCESSES; IMIDAZOLES; MOLECULAR WEIGHT; MYOCARDIAL CONTRACTION; PAPILLARY MUSCLES; PURKINJE FIBERS; RABBITS;

EID: 10144247266     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199608000-00002     Document Type: Article

References (50)

1. Greene HL, Roden DM, Katz RJ, Woosley RL, Salerno DM, Henthorn RW, and the CAST Investigators. The Cardiac Arrhythmia Suppression Trial: first CAST . . . then CAST-II. J Am Coll Cardiol 1992;19:894-8.
2. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993;270:1589-95.
3. Vaughan Williams EM. Significance of classifying antiarrhythmic actions since the Cardiac Arrhythmia Suppression Trial. J Clin Pharmacol 1991;31:123-35.
4. Brugada J, Boersma L, Kirchof C, Allessie M. Proarrhythmic effects of flecainide. Experimental evidence for increased susceptibility to reentrant arrhythmias. Circulation 1991;84:1808-18.
5. Scherlag BJ, Patterson E, Berbari E, Lazzara R. Slow conduction in experimental arrhythmias: mechanisms and role in reentry. In: Fisch C, Surawicz B, eds. Cardiac electro physiology and arrhythmias. New York: Elsevier Science Publishing, 1991;96-107.
6. Singh BN, Ahmed R. Class III antiarrhythmic drugs. Curr Opin Cardiol 1994;9:12-22.
7. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 1990;81:686-90.
8. Katritsis D, Camm AJ. New class III antiarrhythmic drugs. Eur Heart J 1993;14(suppl H):93-9.
9. Roden DM. Current status of class III antiarrhythmic drug therapy. Am J Cardiol 1993;72:44B-9B.
10. Singh BN, Vaughan Williams EM. A third class of antiarrhythmic action: effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle of MJ1999 and AH3474. Br J Pharmacol 1970; 39:675-89.
11. Carlsson L, Abrahamsson C, Anderson B, Duker G, Schiller-Linhardt G. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarizations. Cardiovasc Res 1993; 27:2186-93.
12. Fazekas T, Mabo P, Berlin KD, Scherlag BJ, Lazzara R. Comparative electrophysiological effects of a new chemical class of anti-arrhythmic agents, 3,7-diheterabicyclo[3.3.1]-nonanes, in the 1-4-day-old infarcted dog heart [Abstract]. Physiologist 1992;35:221.
13. Smith GS, Thompson MD, Berlin KD, Holt EM, Scherlag BJ, Patterson E, Lazzara R. A study of the synthesis and antiarrhythmic properties of selected 3,7-diheterabicyclo-[3.3.1]nonanes with substituents at the 2,4-positions and at the 9-position. Eur J Med Chem 1990;25:1-8.
14. Thompson MD, Smith GS, Berlin KD, et al. Synthesis and antiarrhythmic properties of novel 3-selena-7-azabicyclo-[3.3.1]nonanes and derivatives. Single-crystal x-ray diffraction analysis of 7-benzyl-3-selena-7-azabicyclo[3.3.1]-nonane-9-one and 7-benzyl-3-selena-7-azabicyclo[3.3.1]-nonane hydroperchlorate. J Med Chem 1987;30:780-8.
15. Fazekas T, Scherlag BJ, Mabo P, Patterson E, Lazzara R. Facilitation of reentry by lidocaine in experimental myocardial infarction. Am Heart J 1994;127:345-52.
16. Scherlag BJ, Patterson E, Lazzara R. Advantages of an acute experimental preparation that mimics clinical arrhythmias. J Electrocardiol 1988;S61-3.
17. Scherlag BJ, Patterson E, Lazzara R, Bailey BR, Thompson MD, Berlin KD. Comparative electrophysiological and hemodynamic actions of BRB-I-28 and lidocaine in the normal and infarcted dog heart. J Electrophysiol 1988;2:461-77.
18. Wiesfeld ACP, Crijns HJGM, Tobé TJM, et al. Electropharmacologic effects and pharmacokinetics of almokalant, a new class III antiarrhythmic, in patients with healed or healing myocardial infarcts and complex ventricular arrhythmias. Am J Cardiol 1992;70:990-6.
19. Fazekas T, Scherlag BJ, Poty H, Patterson E, Lazzara R. Antiarrhythmic/proarrhythmic profile of a new agent GLG-V-13 compared to lidocaine in the 1-4-day-old infarcted canine heart [Abstract]. Eur Heart J 1994;15:392.
20. Fazekas T, Scherlag BJ, Mabo P, et al. The antiarrhythmic-proarrhythmic and inotropic profile of two new agents, BRB-I-28 and GLG-V-13: actions in the 1-4-day-old infarcted canine heart [Abstract]. PACE 1993;16:925.
21. Duker G, Almgren O, Axenborg JE. Computerized evaluation of drug-induced changes in guinea-pig epicardial monophasic action potentials. Pharmacol Toxicol 1988;63: 85-90.
22. Axenborg JE, Hirsch I. A PC-based on-line system for physiological in vivo and in vitro experiments. Comput Methods Programs Biomed 1993;41:55-67.
23. Franz MR. Method and theory of monophasic action potential recording. Prog Cardiovasc Dis 1991;33:347-68.
24. Patterson E, Jackman WM, Scherlag BJ, Lazzara R. The monophasic action potential in clinical cardiology. Clin Cardiol 1991;14:505-10.
25. Harris AS. Delayed development of ventricular ectopic rhythms following experimental coronary occlusion. Circulation 1950;1:1318-28.
26. Lynch JJ, Heaney LA, Wallace A, Gehret JG, Stein BS. Failure of lidocaine to suppress lethal ischemic ventricular arrhythmias in a canine model of previous myocardial infarction. J Cardiovasc Pharmacol 1990;16:41-9.
27. Scherlag BJ, Abelleira JL, Samet P. Electrode catheter recordings from the His bundle and left bundle in the intact dog. In: Kao FF, Koizumi K, Vassale M, eds. Research in physiology. Bologna: Aulo Gaggi, 1971:223-38.
28. Brachmann J, Kabell G, Scherlag BJ, Harrison L, Lazzara R. Analysis of interectopic activation patterns during sustained ventricular tachycardia. Circulation 1983;67:449-56.
29. Patterson E, Scherlag BJ, Lazzara R. Electrophysiologic actions of clofilium and lidocaine in ischemically injured canine epicardium. J Pharmacol Exp Ther 1992;262:375-82.
30. Sager PT, Perlmutter RA, Rosenfeld LE, Batsford WP. Antiarrhythmic drug exacerbation of ventricular tachycardia inducibility during electrophysiologic study. Am Heart J 1992; 123:926-33.
31. Patterson E, Shlafer M, Walden KM, Khazaeli MB, Montgomery DG, Lucchesi BR. Changes in cardiac muscle function and biochemistry produced by long-term amiodarone and amiodarone + triiodthyronine administration in the rabbit. Pharmacology 1987;35:130-40.
32. Wohlfart B. Analysis of the mechanical alternans in rabbit papillary muscle. Acta Physiol Scand 1982;115:405-14.
33. Chen CL, Sangiah S, Roder JD, et al. Determination of GLG-V-13, a novel antiarrhythmic agent, in plasma and urine by high-performance liquid chromatography. Liquid Chromatogr 1994;17:913-27.
34. Tytgat J, Verecke J, Carmeliet E. A combined study of sodium current and T-type calcium current in isolated cardiac cells. Pflugers Arch 1990;417:142-8.
35. + current by almokalant in rabbit ventricular myocytes. Circulation 1993;73:857-68.
36. Fazekas T, Scherlag BJ, Mabo P, et al. The comparative antiarrhythmic and proarrhythmic activity of a 3,7-diheterabicyclo[3.3.1]nonane, BRB-I-28, and lidocaine in the 1-4-day-old infarcted dog heart. Acta Physiol Hung 1993;81:297-307.
37. Patterson E, Lynch JJ, Luchessi BR. Antiarrhythmic and antifibrillatory actions of the β adrenergic receptor antagonist, dl-sotalol. J Pharmacol Exp Ther 1984;230:519-26.
38. Lis R, Morgan TK, Marisca AJ Jr, et al. Synthesis of novel (aryloxy) propanolamines and related compounds possessing both class II and class III antiarrhythmic activity. J Med Chem 1990;33:2883-91.
39. Almgren O, Bergstrand R, Bäärnhielm C, Duker G. H234/09 (PINN: almokalant) - a new class III antiarrhythmic compound. Cardiovasc Drugs Ther 1991;5(suppl 3):401.
40. Cross PE, Arrowsmith JE, Thomas GH, Gwilt M, Burges RA, Higgins AJ. Selective class III antiarrhythmic agents. 1. Bis(arylalkyl)amines. J Med Chem 1990;33:1151-5.
41. K blocking drugs, UK-68,798 (dofetilide) and E-4031. Cardiovasc Res 1993;27:861-7.
42. Argentieri TM, Carroll MS, Sullivan ME. Cellular electrophysiological effects of the class III antiarrhythmic agents sematilide and clofilium on rabbit atrial tissues. J Cardiovasc Pharmacol 1991;18:167-74.
43. Patterson E, Scherlag BJ, Berlin KD, Lazzara R. Electrophysiologic actions of BRB-I-28 in ischemically injured canine myocardium. J Cardiovasc Pharmacol 1993;21:637-46.
44. Gough WB, El-Sherif N. The differential response of normal and ischaemic Purkinje fibres to clofilium, d-sotalol and bretylium. Cardiovasc Res 1989;23:554-9.
45. Freigang KD, Schoels W, Sterns LD, et al. Differential effect of d-sotalol on normal and infarcted tissue in the canine infarct model. J Am Coll Cardiol 1994;23:398A.
46. Carlsson L, Abrahamsson C, Drews L, Duker G. Antiarrhythmic effects of potassium channel openers in rhythm abnormalities related to delayed repolarization. Circulation 1992;85:1491-500.
47. Campbell JT. Cellular electrophysiological effects of D- and DL-sotalol in guinea-pig sinoatrial node, atrium and ventricle and human atrium: differential tissue sensitivity. Br J Pharmacol 1987;308:593-9.
48. Josephson MA, Singh BN. Hemodynamic effects of class III antiarrhythmic agents. In: Singh BN, ed. Control of cardiac arrhythmias by lengthening repolarization. Mount Kisco, NY: Futura Publishing, 1988;153-73.
49. Patterson E, Scherlag BJ, Berlin KD, Lazzara R. Electro-physiological actions of BRB-I-28 in canine myocardial tissues. J Pharmacol Exp Ther 1991;259:558-65.
50. Carlsson L, Drews L, Duker G, Schiller-Linhardt G. Attenuation of proarrhythmias related to delayed repolarization by low-dose lidocaine in the anesthetized rabbit. J Pharmacol Exp Ther 1993;267:1076-80.